The company's only path to continued listing is a successful Panel hearing, which is discretionary. Given the recent dilutive offering and lack of a compliance period, the risk of eventual delisting is high. Monitor for the hearing date and any Panel decision; a denial would trigger immediate suspension and likely OTC trading.
Price Chart
Executive Summary
Moleculin Biotech received a Nasdaq Staff Determination Letter on September 15, 2026, stating that its common stock closing bid price has been below $1.00 for 30 consecutive business days. Because the company effected a 1-for-25 reverse stock split on December 1, 2025, it is not eligible for the standard 180-day compliance period. The company intends to request a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting pending the Panel's decision, but there is no assurance of regaining compliance.
Key Facts
- Nasdaq notified Moleculin on September 15, 2026 that bid price was below $1.00 for 30 consecutive business days (July 31, 2026 through September 11, 2026)
- Company is ineligible for the standard 180-day compliance period due to a 1-for-25 reverse stock split effected on December 1, 2025
- Company intends to request a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting pending the Panel's decision
- No assurance that continued listing will be granted or that compliance can be regained
- Cross-filing context: a deeply dilutive public offering at $0.75 per share was filed on August 3, 2026, with pro forma shares more than doubling
Financial Impact
Delisting risk is severe; the company has no standard compliance period and must rely on a discretionary Panel hearing. The recent dilutive offering at $0.75 per share (66% discount to prior close) underscores severe capital constraints.
Risk Factors
- Nasdaq Hearings Panel may deny the request for continued listing, leading to suspension and delisting
- Even if the Panel grants continued listing, the company may not be able to maintain compliance with the minimum bid price requirement
- Delisting would severely reduce institutional ownership and liquidity, and could trigger defaults on debt or other obligations
- The company's recent dilutive offering at a 66% discount signals ongoing capital needs and shareholder dilution
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-030757 |
| Document: 0001437749-26-030757-index-headers.html | 0001437749-26-030757 |
| Document: 0001437749-26-030757-index.html | 0001437749-26-030757 |
| Document: 0001437749-26-030757.txt | 0001437749-26-030757 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $6.19 | awaiting T+20 | — | $8.30 (+34.09%) |
Oct 16, 2026 11d ago | 8-K | $0.2804 | awaiting T+20 | — | $8.30 (+2860.06%) |
Oct 9, 2026 17d ago | 8-K | $0.4139 | awaiting T+20 | — | $8.30 (+1905.32%) |
Oct 5, 2026 22d ago | 8-K | $0.4766 | awaiting T+20 | — | $8.30 (+1641.50%) |
Sep 29, 2026 28d ago | 8-K | $0.5264 | awaiting T+20 | — | $8.30 (+1476.75%) |
Sep 29, 2026 28d ago | Press Release | $0.5264 | awaiting T+20 | — | $8.30 (+1476.75%) |
Sep 28, 2026 29d ago | 8-K | $0.5690 $7.09 | ▲ +1145.17% | ▲ +1145.20% | $8.30 (+1358.70%) |
Sep 25, 2026 4w ago | 8-K | $0.6016 $6.50 | ▲ +980.45% | ▲ +981.93% | $8.30 (+1279.65%) |
Sep 23, 2026 4w ago | 8-K | $0.5279 $6.31 | ▲ +1095.30% | ▲ +1094.61% | $8.30 (+1472.27%) |
Sep 18, 2026 5w ago | 8-K | $0.5202 | awaiting T+20 | — | $8.30 (−1495.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers